Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Motivation

<< Previous

Bullboard Posts

Next >>

Comment by snobeion Mar 31, 2021 10:21am

283 Views

Post# 32913433

RE:Motivation

Thanks 4 the post j4p. Yup. I think most of us HAVE to agree. And least i do. No choice. I do believe that the Sheiks money (or more of it ) is still coming just waiting for the C19 trial which will hopefully change the MV. In response to my post, i will accept ..."way to go Einstein" glta longs. Don if u were a football coach u would have been relegated long ago

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market